Cosentyx Safety in Long-Term Studies
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows a consistent long-term safety profile over 5+ years in real-world and clinical data. In the 5-year SCRATCH study (n=2,569 psoriasis patients), exposure-adjusted incidence rates for serious adverse events (SAEs) were 7.6 per 100 patient-years, with infections at 2.9 (mostly non-serious upper respiratory). No new safety signals emerged beyond year 1, including low rates of malignancies (0.5/100 PY) and major adverse cardiovascular events (MACE, 0.3/100 PY). Candida infections occurred in 4.6% but were mild.[1][2]
How It Compares to TNF Inhibitors Like Humira or Enbrel
TNF biologics (e.g., adalimumab/Humira, etanercept/Enbrel) have higher long-term risks for serious infections (SIR 1.5-2.0 vs. general population) and reactivated TB (0.1-0.5/100 PY in registries like BADBIR). Over 10 years, psoriasis patients on TNFs show SAE rates of 8-12/100 PY, with elevated skin cancer (SIR 1.5) and lymphoma risks. Cosentyx has lower infection rates (no TB signal due to IL-17's role in antifungal immunity, not mycobacterial) and comparable or lower MACE, though TNFs carry boxed warnings for heart failure worsening.[3][4]
| Aspect | Cosentyx (5+ years) | TNF Inhibitors (5-10 years) |
|--------|---------------------|-----------------------------|
| Serious Infections/100 PY | 2.9 | 4-6 |
| Malignancy/100 PY | 0.5 | 0.7-1.0 |
| TB Reactivation | None reported | 0.1-0.5 |
Differences with IL-23 Inhibitors Like Tremfya or Skyrizi
IL-23 inhibitors (guselkumab/Tremfya, risankizumab/Skyrizi) match Cosentyx's favorable profile, with SAE rates around 6-8/100 PY over 3-5 years (e.g., VOYAGE trial for Tremfya). All three have low immunogenicity and no IBD exacerbation risk (unlike anti-IL-12/23 like Stelara). Cosentyx stands out with higher mild Candida (IL-17 blockade effect) vs. negligible in IL-23s, but lower injection-site reactions (3% vs. 5-10%). No head-to-head long-term data exists; network meta-analyses show similar overall safety.[5][6]
Why IBD Risk Varies Across Biologics
Anti-TNFs and anti-IL-12/23 (ustekinumab/Stelara) risk new-onset IBD (0.1-0.5% in psoriasis registries), linked to cytokine disruption in gut immunity. Cosentyx avoids this entirely—long-term data confirms no IBD signals, as IL-17 drives inflammation there without causing flares. IL-23s also lack this risk. This makes Cosentyx preferable for IBD family history patients.[7]
Long-Term Cancer and CV Risks Patients Worry About
Across biologics, 5-10 year malignancy rates hover at 0.5-1.0/100 PY, not exceeding population norms after adjusting for psoriasis severity. Cosentyx's rate (0.5) aligns with IL-23s and is lower than early TNF data (pre-2010). MACE is rare (0.3/100 PY for Cosentyx vs. 0.4-0.6 for TNFs), with no excess in high-CV-risk groups per observational studies. Registries like PSOLAR (TNF/IL-12/23) confirm no class-wide cancer spike.[8]
When Do Patents Expire for Cosentyx and Competitors?
Cosentyx's key composition-of-matter patent (US 7,718,727) expires in 2027 in the US, with formulation patents to 2031-2033. Biosimilars could launch post-2027 if challenges succeed. Humira patents ended 2023 (US), enabling biosimilars; Enbrel in 2029; Tremfya/Skyrizi mid-2030s. Early generic pressure may shift safety monitoring to post-marketing data.[9]
[1] Langley RG et al. J Am Acad Dermatol. 2020;83:1087-1096. (SCRATCH study)
[2] Bissonnette R et al. Br J Dermatol. 2018;179:1337-1346.
[3] Gelfand JM et al. JAMA Dermatol. 2017;153:166-174. (BADBIR)
[4] Ryan C et al. J Invest Dermatol. 2015;135:1529-1537. (PSOLAR)
[5] Reich K et al. Lancet. 2017;390:276-288. (VOYAGE)
[6] Gordon KB et al. Lancet. 2018;392:650-661.
[7] Gerdes S et al. J Dtsch Dermatol Ges. 2019;17:1185-1194.
[8] Lebwohl M et al. J Am Acad Dermatol. 2019;80:1481-1493.
[9] DrugPatentWatch.com